Drug Pricing & Policy
42 videos · last 6 months shuffled daily, then older videos newest first
▶
37:27 Rep. Scott Peters on the Pill Penalty, PBMs and China
Rep. Scott Peters of San Diego discusses ending the Inflation Reduction Act's "pill penalty", PBM reform, FDA modernization and China's rise in biotechnology as a strategic concern, on the Making Medicine Podcast.
▶
1:46:58 From Wellness App to Digital Health Application: Building a Digital Therapeutic in Europe - E5
GCP-Mindset's Beyond Outcomes talks to Vitadio co-founder Lenka Šomvárska about generating clinical evidence, CE marking and the MDR transition for a type 2 diabetes digital therapeutic.
▶
7:03 Trump's 200% Tariff Plan for Generic Drugs
Deborah Gleeson, professor of public health at La Trobe University, on Donald Trump's plan to tariff imported generic drugs at 100% from 2028 and 200% the year after.
▶
37:40 Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation
Jayson Slotnik, JD, MPH, of Health Policy Strategies and Steve Usdin of BioCentury discuss the future of the FDA, clinical trial efficiency, and the forces shaping biopharmaceutical innovation.
▶
59:57 Congressional Briefing on Gene Therapy for N-of-1 Diseases
ASGCT's Congressional briefing brings together academic researchers, industry leaders and patient advocates on cell and gene therapy and platform-based development for ultrarare and N-of-1 genetic diseases.
▶
25:46 Senator Todd Young on Biotech, China and FDA Reform
Senator Todd Young discusses the risks of relying on China for critical biotech inputs, why FDA speed and regulatory clarity matter, drug pricing and US biotech competitiveness, on the Making Medicine Podcast.
▶
4:13:49 Increasing Access to Nonprescription Drugs
The Duke-Margolis Institute for Health Policy, under a cooperative agreement with the FDA, convenes drug developers, providers and patient representatives on new drug applications for nonprescription drugs, including prescription-to-nonprescription switches.
▶
56:59 Stephanie Morain on Challenges in Research Ethics
Stephanie Morain, PhD Program Director at the Berman Institute, discusses contemporary challenges in research ethics: protecting and respecting research subjects while advancing socially valuable research.
▶
1:01:07 Beyond Patient Knowledge to Inform Decision-Making - Lessons from HTA
Dr Karen Facey and Dr Anke-Peggy Holtorf discuss how patient involvement in health technology assessment has evolved and how patient-based evidence can inform medicines evaluation, reimbursement and access, in a Consilium Scientific seminar.
▶
27:48 What The IRA Means For Oncology Innovation
Duane Schulthess talks to Michael Penn, US Head of Reimbursement and Public Policy at Sanofi, about how the Inflation Reduction Act and Most Favored Nation pricing proposals could affect oncology research.
▶
1:01:17 Net Benefit in Trial-Based Cost-Effectiveness Analysis
A/Prof An Duy Tran explains for the Australian Clinical Trials Alliance how the net benefit framework can strengthen trial-based cost-effectiveness analysis, using a case study of adding vancomycin to cefazolin for arthroplasty prophylaxis.
▶
28:23 Payer Coverage and Access to Cancer Drugs
James Chambers, PhD, of Tufts University School of Medicine, discusses how US payer coverage decisions and step therapy are restricting access to cancer therapies, for the Association for Value-Based Cancer Care.
▶
56:03 Remote Trials and Digital Endpoints in Underserved Indications
Meri Beckwith of Lindus, Simon Bock of Tiefenbacher Group and ReMEdi trial investigator Beata Godlewska discuss how the fully remote Phase IIa ME/CFS trial captured 22 endpoints per patient and what remote designs offer underserved indications.
▶
39:24 Why Good Medical Devices Fail: Reimbursement Strategy with Ali Samiian
Greenlight Guru talks to Ali Samiian of Popular Access Advisors about MedTech reimbursement, the FDA's TAP program and the CMS RAPID program.
▶
1:27:47 Meet the Expert: Shyam Patel, Kevin Strauss, Manar Zaghlula
Shyam Patel, Kevin Strauss and Manar Zaghlula discuss economic and reimbursement perspectives on gene editing therapies.
▶
25:28 Personalised Melanoma Vaccine and US mRNA Research Funding
BBC News speaks to Tom Whipple, host of BBC Inside Science, about a personalised mRNA vaccine that stopped melanoma returning in a trial, and how US cuts to mRNA vaccine research funding could affect health outcomes.
▶
51:04 Ethical and Strategic Challenges of CAR-T Commercialisation
In a Consilium Scientific seminar, Stephany Saarti examines the strategic, operational and ethical challenges of advanced immuno-oncology therapies such as CAR-T, from evidence generation to reimbursement and access, and introduces the VERITAS framework.
▶
1:03:42 Surrogate Endpoints in Kidney Disease: What They Mean for Patient Access
A CAPT-ACTP 2026 conference panel examines surrogate endpoints in trials for immune-mediated glomerular diseases and how health technology assessment treats that evidence when deciding reimbursement and patient access.
▶
56:13 First-in-Human MEAI Trial: Yale & Johns Hopkins Researchers Discuss CMND-100
Investigators from Yale and Johns Hopkins, with Clearmind CEO Adi Zuloff-Shani, discuss the first-in-human trial of CMND-100, an MEAI-based compound for alcohol use disorder.
▶
1:01:27 Evidence Beyond FEV1 for Respiratory Biologics
A Lindus Health panel discusses designing Phase 3b, Phase 4 and prospective real-world evidence studies for asthma and COPD biologics that meet payor and HTA needs, including remote spirometry and digital biomarkers.
▶
55:59 Gene Therapies Demystified: Policy, Access, and the Road Ahead
John Feore, Director of Health Policy & Advocacy for the Institute for Gene Therapies, reviews gene therapy policy at the FDA, HHS and Congress and how patient groups work on access, for the CMT Research Foundation.
▶
30:58 CAR-T for NMOSD: A Phase 1 Trial
Dr. Michael Levy and Dr. Benjamin Greenberg describe for SRNA an autologous Phase 1 CAR-T study in aquaporin-4-positive NMOSD at Mass General and UT Southwestern, covering eligibility, risks and lessons for neuroimmune research.
▶
20:04 Pharma Commerce on Domestic Manufacturing and the German Pricing Standoff
The FDA has named the first seven manufacturers in its PreCheck pilot, from more than eighty applicants. The programme moves FDA scrutiny of facility readiness earlier, before problems become approval-blocking deficiencies.
▶
50:04 China's Biotech Rise and Clinical Trials
Tim Scott, President and CEO of Biocom, shares observations from a biotech delegation to Shanghai, including how China's investigator-initiated trials work, trial-ready cohorts, licensing and what it means for U.S. competition, for the Making Medicine Podcast.